Apogenix reveals PFS data for brain cancer drug with OS to follow
This article was originally published in Scrip
Executive Summary
As Apogenix announced the figures that confirm that the primary objective of its Phase II proof-of-concept trial investigating its lead product, APG101, as a second line treatment of glioblastoma multiforme (GBM), had been met, company CEO and CFO, Dr Thomas Höger told Scrip that he expects to unveil overall survival data from the study in the fourth quarter of this year.